帝王保藏：一诺千金。
EMPEROR-Preserved: A promise fulfilled.
机构信息
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Departments of Surgery and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
出版信息
Cell Metab. 2021 Nov 2;33(11):2099-2103. doi: 10.1016/j.cmet.2021.10.011.
Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest unmet needs in medicine. In the EMPEROR-Preserved trial, recently reported in the NEJM, the SGLT2 inhibitor empagliflozin reduced the primary outcome of heart failure hospitalizations and cardiovascular death by 21% in patients with HFpEF. This represents an important breakthrough in the war against heart failure.
射血分数保留的心衰（HFpEF）是目前医学领域尚未满足的最大需求之一。最近在《新英格兰医学杂志》（NEJM）上报道的 EMPEROR-Preserved 试验中，钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂恩格列净使 HFpEF 患者的主要终点——心衰住院和心血管死亡降低了 21%。这是对抗心衰的一场重要突破。
Zotero 插件